Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NovoCure Limited
  6. News
  7. Summary
    NVCR   JE00BYSS4X48

NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
74.52 USD   +1.66%
07/05Evercore ISI Downgrades NovoCure to Underperform From In-Line
MT
07/01Novocure to Report Second Quarter 2022 Financial Results
BU
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NovoCure's Shares Rise After HC Wainwright Initiates Coverage at Buy

05/16/2022 | 01:22pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about NOVOCURE LIMITED
07/05Evercore ISI Downgrades NovoCure to Underperform From In-Line
MT
07/01Novocure to Report Second Quarter 2022 Financial Results
BU
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
CI
06/21NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination ..
MT
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
BU
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
CI
06/10NOVOCURE LTD : Change in Directors or Principal Officers, Amendments to Articles of Inc. o..
AQ
06/06HC Wainwright Initiates NovoCure at Buy, Sets Price Target at $115
MT
06/03Novocure Falls 5%, Zai Lab Rises 8%; Companies Report Study Results
DJ
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 552 M - -
Net income 2022 -62,6 M - -
Net Debt 2022 293 M - -
P/E ratio 2022 -128x
Yield 2022 -
Capitalization 7 794 M 7 794 M -
EV / Sales 2022 14,7x
EV / Sales 2023 13,6x
Nbr of Employees 1 167
Free-Float 86,7%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 74,52 $
Average target price 99,11 $
Spread / Average Target 33,0%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-2.37%7 794
MASIMO CORPORATION-53.58%7 585
SHOCKWAVE MEDICAL, INC.13.17%7 224
GETINGE AB-38.83%6 246
IRAY TECHNOLOGY COMPANY LIMITED-6.22%5 032
PENUMBRA, INC.-55.97%4 767